Abstract

Mouse cortical GABAergic synaptosomes possess presynaptic inhibitory GABAB autoreceptors. Accordingly, (±)baclofen (3 μM) inhibits in a CGP53423-sensitive manner the 12 mM KCl-evoked release of preloaded [3H]GABA. Differently, the existence of presynaptic release-regulating metabotropic glutamate type 1 (mGlu1) heteroreceptors in these terminals is still matter of discussion, although confocal microscopy unveiled the existence of mGlu1α with GABAB1 or GABAB2 proteins in cortical VGAT-positive synaptosomes. The group I mGlu agonist 3,5-DHPG failed to modify on its own the 12 mM KCl-evoked [3H]GABA exocytosis from cortical nerve endings, but, when added concomitantly to the GABAB agonist, it significantly reduced the 3 μM (±)baclofen-induced inhibition of [3H]GABA exocytosis. Conversely, the mGlu1 antagonist LY367385 (0.03–1 μM), inactive on its own on GABA exocytosis, amplified the 3 μM (±)baclofen-induced inhibition of [3H]GABA overflow. The ( ± )baclofen-induced inhibition of [3H]GABA exocytosis was more pronounced in cortical synaptosomes from Grm1crv4/crv4 mice, which bear a spontaneous mutation of the Grm1 gene leading to the functional inactivation of the mGlu1 receptor. Inasmuch, the expression of GABAB2 receptor protein in cortical synaptosomal lysates from Grm1crv4/crv4 mice was increased when compared to controls. Altogether, these observations seem best interpreted by assuming that mGlu1 coexist with GABAB receptors in GABAergic cortical synaptosomes, where they control GABA receptors in an antagonist-like manner. We then asked whether the mGlu1-mediated control of GABAB receptors is restricted to GABAergic terminals, or if it occurs also in other subpopulations of nerve endings. Release-regulating GABAB receptors also exist in glutamatergic nerve endings. (±)baclofen (1 μM) diminished the 12 mM KCl-evoked [3H]D-aspartate overflow. Also in these terminals, the concomitant presence of 1 μM LY367385, inactive on its own, significantly amplified the inhibitory effect exerted by (±)baclofen on [3H]D-aspartate exocytosis. Confocal microscopy confirmed the colocalization of mGlu1 with GABAB1 and GABAB2 labeling in vesicular glutamate type1 transporter-positive particles. Our results support the conclusion that mGlu1 receptors modulate in an antagonist-like manner presynaptic release-regulating GABAB receptors. This receptor–receptor interaction could be neuroprotective in central disease typified by hyperglutamatergicity.

Highlights

  • Dimerization of G protein-coupled receptors (GPCRs) is a necessity for signal transduction, leading from agonist binding to G protein activation

  • We analyzed the colocalization of mGlu1α receptor protein with GABAB1 and GABAB2 subunits

  • The impossibility to perform a triple-labeling quantification, does not allow speculating the percentage of colocalization of the mGlu1 and GABAB receptor proteins in the GABAergic synaptosomal particles, there is a high overlapping of the mGlu1α with either the GABAB1 and GABAB2 stainings in the VGAT-positive particles (Figures 1D,H, merge, white)

Read more

Summary

Introduction

Dimerization of G protein-coupled receptors (GPCRs) is a necessity for signal transduction, leading from agonist binding to G protein activation. Metabotropic glutamate (mGlu) receptors exist as either homo or heterodimers (Doumazane et al, 2010; Nicoletti et al, 2011), while GABAB receptors are heterodimers (Pin and Bettler, 2016). GABAB receptors have a widespread distribution in the central nervous system (CNS) where they mediate the inhibition of chemical transmission. They preferentially locate presynaptically, close to the site of transmitter release, and contribute to control synaptic plasticity. GABAB receptors exist as autoreceptors on GABAergic nerve terminals (Pittaluga et al, 1987) and as heteroreceptors on non-GABAergic terminals (i.e., the glutamatergic and the peptidergic nerve endings, Bonanno and Raiteri, 1993)

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.